Related Experiment Video
Updated: Mar 20, 2026
Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Cholestasis in Preterm Infants
1Division of Neonatology, Department of Pediatrics, University of Minnesota, 2450 Riverside Avenue, 6th Floor, East Building, Delivery Code: 8952A, Minneapolis, MN 55454, USA.
Insights
Cholestasis in preterm infants is complex, with risk factors like prematurity and parenteral nutrition. Early enteral feeding is key for prevention and management of this liver condition.
Area of Science:
- Neonatal Medicine
- Pediatric Gastroenterology
- Hepatology
Background:
- Cholestasis in preterm infants presents a significant clinical challenge.
- It arises from multifactorial causes including prematurity, lack of enteral nutrition, and parenteral nutrition (PN).
- Soy-based lipid emulsions in PN are suspected contributors to liver injury.
Purpose of the Study:
- To review the etiology, risk factors, and management of cholestasis in preterm infants.
- To highlight the role of inflammation and current therapeutic limitations.
- To emphasize the importance of early enteral nutrition.
Main Methods:
- Literature review of studies on cholestasis in preterm neonates.
- Analysis of risk factors, diagnostic methods (direct bilirubin), and adverse outcomes.
- Evaluation of current medical therapies and preventative strategies.
Main Results:
- Key risk factors identified: prematurity, intestinal injury, prolonged PN, and sepsis.
- PN-associated liver injury linked to soy-based lipid emulsions and inflammation.
- Medical therapies show inconsistent efficacy.
Conclusions:
- Early enteral feeding, as tolerated, is the most effective strategy for preventing and managing cholestasis in preterm infants.
- Close monitoring of direct bilirubin levels is crucial for diagnosis and tracking.
- Adverse outcomes underscore the need for timely and appropriate interventions.
Abstract:
Cholestasis in preterm infants has a multifactorial etiology. Risk factors include degree of prematurity, lack of enteral feeding, intestinal injury, prolonged use of parenteral nutrition (PN), and sepsis. Soy-based parenteral lipid emulsions have been implicated in the pathophysiology of PN-associated liver injury. Inflammation plays an important role. Medical therapies are used; however, their effects have not consistently proven effective. Evaluation of cholestasis involves laboratory work; direct bilirubin levels are used for diagnosis and trending. Adverse outcomes include risk for hepatobiliary dysfunction, irreversible liver failure, and death. Early enteral feedings as tolerated is the best way to prevent and manage cholestasis.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...